{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:55:34Z","timestamp":1790776534478,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hanmi Pharmaceutical company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Non-erosive reflux disease (NERD) pathogenesis has not been thoroughly evaluated. Here, we assessed the response of patients with NERD to proton pump inhibitor (PPI) therapy; changes in the microbiome and biologic marker expression in the esophageal mucosa were also evaluated. Patients with NERD (n\u2009=\u200955) received esomeprazole (20\u00a0mg) for eight weeks. The treatment response was evaluated at baseline, week four, and week eight. Esophageal mucosal markers and oropharyngeal and esophageal microbiomes were analyzed in patients who underwent upper gastrointestinal endoscopy at screening (n\u2009=\u200918). Complete and partial response rates at week eight were 60.0% and 32.7% for heartburn, and 61.8% and 29.1% for regurgitation, respectively. The expressions of several inflammatory cytokines, including IL-6, IL-8, and NF-\u03baB, were decreased at week eight.\n                    <jats:italic>Streptococcus<\/jats:italic>\n                    ,\n                    <jats:italic>Haemophilus<\/jats:italic>\n                    ,\n                    <jats:italic>Prevotella<\/jats:italic>\n                    ,\n                    <jats:italic>Veillonella<\/jats:italic>\n                    ,\n                    <jats:italic>Neisseria<\/jats:italic>\n                    , and\n                    <jats:italic>Granulicatella<\/jats:italic>\n                    were prevalent regardless of the time-point (baseline vs. week eight) and organ (oropharynx vs. esophagus). The overall composition of oropharyngeal and esophageal microbiomes showed significant difference (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.004), which disappeared after PPI therapy. In conclusion, half-dose PPI therapy for eight weeks could effectively control NERD symptoms. The expression of several inflammatory cytokines was reduced in the esophagus, and oropharyngeal and esophageal microbiomes in patients with NERD showed significant difference. However, the microbial compositions in the oropharynx and esophagus were not affected by PPI therapy in this study. Impact of PPI on the microbiome in patients with NERD should be more investigated in future studies.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-72082-8","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T06:03:22Z","timestamp":1600236202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of non-erosive reflux disease and dynamics of the esophageal microbiome: a prospective multicenter study"],"prefix":"10.1038","volume":"10","author":[{"given":"Chan Hyuk","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung In","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hyung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Joo","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kil","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"72082_CR1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1365-2036.2009.04013.x","volume":"29","author":"R Fass","year":"2009","unstructured":"Fass, R. et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol. Ther. 29, 1261\u20131272 (2009).","journal-title":"Aliment Pharmacol. Ther."},{"key":"72082_CR2","doi-asserted-by":"crossref","first-page":"6417526","DOI":"10.1155\/2018\/6417526","volume":"2018","author":"Z Khan","year":"2018","unstructured":"Khan, Z. et al. On-demand therapy with proton pump inhibitors for maintenance treatment of nonerosive reflux disease or mild erosive esophagitis: a systematic review and meta-analysis. Gastroenterol. Res. Pract. 2018, 6417526 (2018).","journal-title":"Gastroenterol. Res. Pract."},{"key":"72082_CR3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5056\/jnm.2010.16.1.8","volume":"16","author":"T Hershcovici","year":"2010","unstructured":"Hershcovici, T. & Fass, R. Nonerosive Reflux Disease (NERD)\u2014an update. J. Neurogastroenterol. Motil. 16, 8\u201321 (2010).","journal-title":"J. Neurogastroenterol. Motil."},{"key":"72082_CR4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12876-016-0448-x","volume":"16","author":"E Bayerdorffer","year":"2016","unstructured":"Bayerdorffer, E. et al. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterol. 16, 48 (2016).","journal-title":"BMC Gastroenterol."},{"key":"72082_CR5","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/S0140-6736(06)68932-0","volume":"367","author":"P Moayyedi","year":"2006","unstructured":"Moayyedi, P. & Talley, N. J. Gastro-oesophageal reflux disease. Lancet 367, 2086\u20132100 (2006).","journal-title":"Lancet"},{"key":"72082_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002095.pub5","author":"KE Sigterman","year":"2013","unstructured":"Sigterman, K. E. et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD002095.pub5 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"72082_CR7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1542-3565(04)00288-5","volume":"2","author":"BB Dean","year":"2004","unstructured":"Dean, B. B. et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin. Gastroenterol. Hepatol. 2, 656\u2013664 (2004).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"72082_CR8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.mcg.0000225631.07039.6d","volume":"41","author":"R Fass","year":"2007","unstructured":"Fass, R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J. Clin. Gastroenterol. 41, 131\u2013137 (2007).","journal-title":"J. Clin. Gastroenterol."},{"key":"72082_CR9","first-page":"1901","volume":"97","author":"R Fass","year":"2002","unstructured":"Fass, R. & Ofman, J. J. Gastroesophageal reflux disease\u2013should we adopt a new conceptual framework?. Am. J. Gastroenterol. 97, 1901\u20131909 (2002).","journal-title":"Am. J. Gastroenterol."},{"key":"72082_CR10","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1055\/s-2007-963628","volume":"45","author":"R Fass","year":"2007","unstructured":"Fass, R. Non-erosive reflux disease (NERD) and erosive esophagitis\u2013a spectrum of disease or special entities?. Z Gastroenterol 45, 1156\u20131163 (2007).","journal-title":"Z Gastroenterol"},{"key":"72082_CR11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.gastro.2017.09.047","volume":"154","author":"J Tack","year":"2018","unstructured":"Tack, J. & Pandolfino, J. E. Pathophysiology of gastroesophageal reflux disease. Gastroenterology 154, 277\u2013288 (2018).","journal-title":"Gastroenterology"},{"key":"72082_CR12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nyas.13127","volume":"1381","author":"V Di Pilato","year":"2016","unstructured":"Di Pilato, V. et al. The esophageal microbiota in health and disease. Ann. N Y Acad. Sci. 1381, 21\u201333 (2016).","journal-title":"Ann. N Y Acad. Sci."},{"key":"72082_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12389","author":"YS Jung","year":"2017","unstructured":"Jung, Y. S. et al. Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis. Helicobacter https:\/\/doi.org\/10.1111\/hel.12389 (2017).","journal-title":"Helicobacter"},{"key":"72082_CR14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.11138\/orl\/2017.10.3.229","volume":"10","author":"D Lauritano","year":"2017","unstructured":"Lauritano, D. et al. Focus on periodontal disease and colorectal carcinoma. Oral Implantol. (Rome) 10, 229\u2013233 (2017).","journal-title":"Oral Implantol. (Rome)"},{"key":"72082_CR15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.chom.2013.07.007","volume":"14","author":"AD Kostic","year":"2013","unstructured":"Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207\u2013215 (2013).","journal-title":"Cell Host Microbe"},{"key":"72082_CR16","doi-asserted-by":"crossref","first-page":"25271","DOI":"10.1038\/srep25271","volume":"6","author":"CH Park","year":"2016","unstructured":"Park, C. H. et al. Role of Fusobacteria in the serrated pathway of colorectal carcinogenesis. Sci. Rep. 6, 25271 (2016).","journal-title":"Sci. Rep."},{"key":"72082_CR17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1053\/j.gastro.2009.04.046","volume":"137","author":"L Yang","year":"2009","unstructured":"Yang, L. et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 137, 588\u2013597 (2009).","journal-title":"Gastroenterology"},{"key":"72082_CR18","doi-asserted-by":"crossref","first-page":"e0129055","DOI":"10.1371\/journal.pone.0129055","volume":"10","author":"A Gall","year":"2015","unstructured":"Gall, A. et al. Bacterial composition of the human upper gastrointestinal tract microbiome is dynamic and associated with genomic instability in a Barrett\u2019s Esophagus cohort. PLoS ONE 10, e0129055 (2015).","journal-title":"PLoS ONE"},{"key":"72082_CR19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s40168-018-0611-4","volume":"6","author":"NP Deshpande","year":"2018","unstructured":"Deshpande, N. P. et al. Signatures within the esophageal microbiome are associated with host genetics, age, and disease. Microbiome 6, 227 (2018).","journal-title":"Microbiome"},{"key":"72082_CR20","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1136\/gutjnl-2016-311715","volume":"65","author":"KM Fock","year":"2016","unstructured":"Fock, K. M. et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett\u2019s oesophagus. Gut 65, 1402\u20131415 (2016).","journal-title":"Gut"},{"key":"72082_CR21","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3748\/wjg.v19.i16.2514","volume":"19","author":"NB Zschau","year":"2013","unstructured":"Zschau, N. B. et al. Gastroesophageal reflux disease after diagnostic endoscopy in the clinical setting. World J. Gastroenterol. 19, 2514\u20132520 (2013).","journal-title":"World J. Gastroenterol."},{"key":"72082_CR22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1365-2036.2009.03948.x","volume":"29","author":"A Eggleston","year":"2009","unstructured":"Eggleston, A. et al. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care\u2013prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Aliment Pharmacol. Ther. 29, 967\u2013978 (2009).","journal-title":"Aliment Pharmacol. Ther."},{"key":"72082_CR23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3349\/ymj.2018.59.8.951","volume":"59","author":"IJ Song","year":"2018","unstructured":"Song, I. J., Kim, H. K., Lee, N. K. & Lee, S. K. Prospective single arm study on the effect of ilaprazole in patients with heartburn but no reflux esophagitis. Yonsei Med. J. 59, 951\u2013959 (2018).","journal-title":"Yonsei Med. J."},{"key":"72082_CR24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1442-2050.2005.00497.x","volume":"18","author":"MM Abdel-Latif","year":"2005","unstructured":"Abdel-Latif, M. M. et al. Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy. Dis. Esophagus 18, 246\u2013252 (2005).","journal-title":"Dis. Esophagus"},{"key":"72082_CR25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.iy.12.040194.001041","volume":"12","author":"PA Baeuerle","year":"1994","unstructured":"Baeuerle, P. A. & Henkel, T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 12, 141\u2013179 (1994).","journal-title":"Annu. Rev. Immunol."},{"key":"72082_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60618-5","volume":"58","author":"EB Kopp","year":"1995","unstructured":"Kopp, E. B. & Ghosh, S. NF-kappa B and rel proteins in innate immunity. Adv. Immunol. 58, 1\u201327 (1995).","journal-title":"Adv. Immunol."},{"key":"72082_CR27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1067\/msy.2001.116672","volume":"130","author":"DS Lind","year":"2001","unstructured":"Lind, D. S. et al. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 130, 363\u2013369 (2001).","journal-title":"Surgery"},{"key":"72082_CR28","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1172\/JCI119848","volume":"100","author":"MA Sovak","year":"1997","unstructured":"Sovak, M. A. et al. Aberrant nuclear factor-kappaB\/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100, 2952\u20132960 (1997).","journal-title":"J. Clin. Invest."},{"key":"72082_CR29","first-page":"2360","volume":"93","author":"N Mori","year":"1999","unstructured":"Mori, N. et al. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 93, 2360\u20132368 (1999).","journal-title":"Blood"},{"key":"72082_CR30","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1128\/MCB.17.7.3629","volume":"17","author":"H Nakshatri","year":"1997","unstructured":"Nakshatri, H. et al. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell Biol. 17, 3629\u20133639 (1997).","journal-title":"Mol. Cell Biol."},{"key":"72082_CR31","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","volume":"336","author":"PJ Barnes","year":"1997","unstructured":"Barnes, P. J. & Karin, M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066\u20131071 (1997).","journal-title":"N. Engl. J. Med."},{"key":"72082_CR32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/01.sla.0000118751.95179.c6","volume":"239","author":"MM Abdel-Latif","year":"2004","unstructured":"Abdel-Latif, M. M. et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett\u2019s metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann. Surg. 239, 491\u2013500 (2004).","journal-title":"Ann. Surg."},{"key":"72082_CR33","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3748\/wjg.v19.i15.2307","volume":"19","author":"K Dvorak","year":"2013","unstructured":"Dvorak, K. & Dvorak, B. Role of interleukin-6 in Barrett\u2019s esophagus pathogenesis. World J. Gastroenterol. 19, 2307\u20132312 (2013).","journal-title":"World J. Gastroenterol."},{"key":"72082_CR34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.mib.2014.11.013","volume":"23","author":"YW Han","year":"2015","unstructured":"Han, Y. W. Fusobacterium nucleatum: a commensal-turned pathogen. Curr. Opin. Microbiol. 23, 141\u2013147 (2015).","journal-title":"Curr. Opin. Microbiol."},{"key":"72082_CR35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5056\/jnm19240","volume":"26","author":"CH Park","year":"2020","unstructured":"Park, C. H. & Lee, S. K. Exploring esophageal microbiomes in esophageal diseases: a systematic review. J. Neurogastroenterol. Motil. 26, 171\u2013179 (2020).","journal-title":"J. Neurogastroenterol. Motil."},{"key":"72082_CR36","doi-asserted-by":"crossref","first-page":"G454","DOI":"10.1152\/ajpgi.00458.2010","volume":"300","author":"HY Zhang","year":"2011","unstructured":"Zhang, H. Y. et al. Cancer-related inflammation and Barrett\u2019s carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett\u2019s cells. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G454-460 (2011).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"72082_CR37","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1074\/jbc.M410994200","volume":"280","author":"SK Manna","year":"2005","unstructured":"Manna, S. K. & Ramesh, G. T. Interleukin-8 induces nuclear transcription factor-kappaB through a TRAF6-dependent pathway. J. Biol. Chem. 280, 7010\u20137021 (2005).","journal-title":"J. Biol. Chem."},{"key":"72082_CR38","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.2016.5657","volume":"315","author":"KB Dunbar","year":"2016","unstructured":"Dunbar, K. B. et al. Association of acute gastroesophageal reflux disease with esophageal histologic changes. JAMA 315, 2104\u20132112 (2016).","journal-title":"JAMA"},{"key":"72082_CR39","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/dote\/11.4.248","volume":"11","author":"D Gagliardi","year":"1998","unstructured":"Gagliardi, D. et al. Microbial flora of the normal esophagus. Dis. Esophagus 11, 248\u2013250 (1998).","journal-title":"Dis. Esophagus"},{"key":"72082_CR40","doi-asserted-by":"crossref","first-page":"e12547","DOI":"10.1111\/hel.12547","volume":"24","author":"CH Park","year":"2019","unstructured":"Park, C. H. et al. Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing. Helicobacter 24, e12547 (2019).","journal-title":"Helicobacter"},{"key":"72082_CR41","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s11136-004-9567-x","volume":"13","author":"AM Rentz","year":"2004","unstructured":"Rentz, A. M. et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual. Life Res. 13, 1737\u20131749 (2004).","journal-title":"Qual. Life Res."},{"key":"72082_CR42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond, A. S. & Snaith, R. P. The hospital anxiety and depression scale. Acta Psychiatr Scand 67, 361\u2013370 (1983).","journal-title":"Acta Psychiatr Scand"},{"key":"72082_CR43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1017\/S1368980008002802","volume":"12","author":"CP Wen","year":"2009","unstructured":"Wen, C. P. et al. Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for Asians. Public Health Nutr. 12, 497\u2013506 (2009).","journal-title":"Public Health Nutr."},{"key":"72082_CR44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.5009\/gnl18408","volume":"13","author":"YH Youn","year":"2019","unstructured":"Youn, Y. H. et al. Long noncoding RNA N-BLR upregulates the migration and invasion of gastric adenocarcinoma. Gut Liver 13, 421\u2013429 (2019).","journal-title":"Gut Liver"},{"key":"72082_CR45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nmeth.f.303","volume":"7","author":"JG Caporaso","year":"2010","unstructured":"Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335\u2013336 (2010).","journal-title":"Nat. Methods"},{"key":"72082_CR46","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/gb-2011-12-6-r60","volume":"12","author":"N Segata","year":"2011","unstructured":"Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).","journal-title":"Genome Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72082-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72082-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72082-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:18:09Z","timestamp":1670336289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-72082-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["72082"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-72082-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"assertion":[{"value":"24 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15154"}}